2016-2023年中国119家医疗机构肝病门诊保肝药用药分析
Analysis of Hepatoprotective Drugs Utilization in Hepatology Outpatients in 119 Chinese Hospitals from 2016 to 2023
武一 1潘晨 1姜静 2程吟楚 3赵莹 1周效竹 1刘冉佳 1崔向丽1
作者信息
- 1. 首都医科大学附属北京友谊医院药学部,北京 100050
- 2. 中国人民解放军火箭军特色医学中心生殖医学中心,北京 100086
- 3. 北京大学第三医院药剂科,北京 100191
- 折叠
摘要
目的 分析国内医院门诊患者的保肝药药物使用特征和药费情况,为合理用药提供参考.方法 收集并统计2016年1月至2023年12月全国9个城市119家医疗机构的保肝药相关门诊处方数据,分析保肝药物的临床应用情况.结果 本研究共调取3 194 167例患者的8 635 977张处方.门诊开具保肝药相关诊断最多的是乙型肝炎(7.59％)、肝硬化(5.11％)和非酒精性脂肪肝炎(4.53％),其中开具1～2种保肝药处方占比98.15％,口服剂型占比97.29％.近8年保肝药的药费总额从8 537.91万元增长至10 980万元,次均药费从85.15元增长至95.52元.甘草酸制剂是最常用的单药保肝方案,多烯磷脂酰胆碱+甘草酸制剂治疗是最常用的联合保肝方案.结论 保肝药药费呈逐年上升趋势,给医保带来一定的负担,本研究对近8年全国肝病门诊保肝药用药情况进行分析,为未来开展保肝药物的综合评价提供基础数据支持.
Abstract
OBJECTIVE To analyze the characteristics and drug cost of hepatoprotective drugs among outpatients in domestic hos-pitals and provide references for rational drug use.METHODS The outpatient prescription data of 119 hospitals in 9 cities from Jan-uary 2016 to December 2023 was collected,and the clinical application of hepatoprotective drugs was analyzed.RESULTS A total of 8 635 977 prescriptions from 3 194 167 patients were obtained in this study.The most frequent diagnoses of hepatoprotective drugs were hepatitis B(7.59％),liver cirrhosis(5.11％)and non-alcoholic steatohepatitis(4.53％).98.15％of prescriptions for 1-2 hepato-protective drugs are prescribed,and oral dosage forms account for 97.29％.The total drug cost of hepatoprotective drugs increased from 85.38 million yuan to 109.8 million yuan,and the average drug cost per time increased from 85.15 yuan to 95.52 yuan.The gly-cyrrhizin preparation was the most used regimen,and the polyene phosphatidylcholine+glycyrrhizin preparation was the most used regi-men.CONCLUSIONS The aggregate costs on hepatoprotective medications appears a consistent annual increase,which brings eco-nomic burden to medical insurance.This study analyzes the trend of hepatoprotective drug costs in the past 8 years,which is of great significance to the drug management of patients with liver disease.
关键词
乙型肝炎/保肝药/处方分析/药费/甘草酸制剂Key words
hepatitis B/hepatoprotective drugs/prescription analysis/drug cost/glycyrrhizin preparation引用本文复制引用
基金项目
国家卫生健康委医院管理研究所医院药学高质量发展研究项目(NIHAYS2302)
北京药学会临床药学研究项目(LCYX-2022-16)
出版年
2024
NETL
NSTL
万方数据